Global GenericsRevenues from Global Generics segment at ?70.2...

Global Generics
Revenues from Global Generics segment at ?70.2 billion in FY12, year-on-year growth of 32% driven by key markets of North America and Russia.

?Revenues from North America at ?31.9 billion in FY12 grew by 62% in local currency over previous year. Revenues in Q4 FY12 at ?8.7 billion represented year-on-year growth of 36% in local currency. In Q4 FY12, revenue share of olanzapine was below $2 million due to lower generic substitution and shelf stock adjustment.
¦Growth was largely driven by new product launches of ziprasidone, fondaparinux, amoxicillin clavulanic acid, products from Shreveport facility and market share expansion in existing products of lansoprazole and omeprazole Mg OTC.